5/16
06:22 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
5/14
08:38 am
nbix
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024 [Yahoo! Finance]
5/14
08:30 am
nbix
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Low
Report
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
5/14
08:07 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $175.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $175.00 price target on the stock.
5/13
05:49 pm
nbix
Voyager Therapeutics up 8% following quarterly beats [Seeking Alpha]
Low
Report
Voyager Therapeutics up 8% following quarterly beats [Seeking Alpha]
5/10
07:56 am
nbix
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? [Yahoo! Finance]
5/9
09:56 am
nbix
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024 [Yahoo! Finance]
5/9
09:45 am
nbix
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
Low
Report
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
5/9
08:35 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults [Yahoo! Finance]
5/9
08:30 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
5/9
02:45 am
nbix
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 [Yahoo! Finance]
Low
Report
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024 [Yahoo! Finance]
5/8
08:40 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults [Yahoo! Finance]
5/8
08:30 am
nbix
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Medium
Report
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
5/7
04:15 pm
nbix
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Medium
Report
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
5/7
08:37 am
nbix
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 [Yahoo! Finance]
5/7
08:30 am
nbix
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
Low
Report
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
5/6
08:36 am
nbix
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring [Yahoo! Finance]
5/6
08:30 am
nbix
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Low
Report
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
5/3
08:00 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Citigroup Inc. from $140.00 to $150.00. They now have a "neutral" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Citigroup Inc. from $140.00 to $150.00. They now have a "neutral" rating on the stock.
5/3
01:23 pm
nbix
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 [Yahoo! Finance]
Low
Report
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 [Yahoo! Finance]
5/3
01:15 pm
nbix
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Neutral
Report
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
5/2
11:04 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Medium
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
5/2
03:58 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $154.00 to $164.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Canaccord Genuity Group Inc. from $154.00 to $164.00. They now have a "buy" rating on the stock.
5/2
03:02 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Guggenheim from $164.00 to $170.00. They now have a "buy" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Guggenheim from $164.00 to $170.00. They now have a "buy" rating on the stock.
5/2
02:07 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $150.00 to $169.00. They now have an "overweight" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Barclays PLC from $150.00 to $169.00. They now have an "overweight" rating on the stock.